ALNYLAM PHARMACEUTICALS, INC. Costs and Expenses
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Costs and Expenses of $1.06 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2026-06-30 was $1.06B, a 34.13% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-12-31 was $965.32M, a 38.23% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-09-30 was $881.04M, a 52.48% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-06-30 was $789.89M, a 29.23% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for fiscal 2025 was $3.21B, a 32.46% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for fiscal 2024 was $2.43B, a 14.91% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for fiscal 2023 was $2.11B, a 15.80% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. costs and expenses for fiscal 2022 was $1.82B, a 17.36% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.06B 10-Q · filed 2026-07-30 | $1.96B 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | $965.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.85B derived: sum of 2 quarters · filed 2026-02-12 | $2.64B derived: sum of 3 quarters · filed 2026-07-30 | $3.21B 10-K · filed 2026-02-12 |
| 2025-09-30 | $881.04M 10-Q · filed 2025-10-30 | $1.67B derived: sum of 2 quarters · filed 2026-07-30 | $2.25B 10-Q · filed 2025-10-30 | $2.95B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $789.89M 10-Q · filed 2026-07-30 | $1.37B 10-Q · filed 2026-07-30 | $2.06B derived: sum of 3 quarters · filed 2026-07-30 | $2.64B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $576.11M 10-Q · filed 2025-05-01 | $1.27B derived: sum of 2 quarters · filed 2026-02-12 | $1.85B derived: sum of 3 quarters · filed 2026-02-12 | $2.46B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $698.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.28B derived: sum of 2 quarters · filed 2026-02-12 | $1.89B derived: sum of 3 quarters · filed 2026-02-12 | $2.43B 10-K · filed 2026-02-12 |
| 2024-09-30 | $577.82M 10-Q · filed 2025-10-30 | $1.19B derived: sum of 2 quarters · filed 2025-10-30 | $1.73B 10-Q · filed 2025-10-30 | $2.28B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $611.21M 10-Q · filed 2025-07-31 | $1.15B 10-Q · filed 2025-07-31 | $1.71B derived: sum of 3 quarters · filed 2026-02-12 | $2.24B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $537.77M 10-Q · filed 2025-05-01 | $1.09B derived: sum of 2 quarters · filed 2026-02-12 | $1.63B derived: sum of 3 quarters · filed 2026-02-12 | $2.18B derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $556.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.09B derived: sum of 2 quarters · filed 2026-02-12 | $1.64B derived: sum of 3 quarters · filed 2026-02-12 | $2.11B 10-K · filed 2026-02-12 |
| 2023-09-30 | $536.66M 10-Q · filed 2024-10-31 | $1.09B derived: sum of 2 quarters · filed 2024-10-31 | $1.55B 10-Q · filed 2024-10-31 | $2.08B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $548.59M 10-Q · filed 2024-08-01 | $1.02B 10-Q · filed 2024-08-01 | $1.54B derived: sum of 3 quarters · filed 2025-02-13 | $2.06B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $469.10M 10-Q · filed 2024-05-02 | $992.75M derived: sum of 2 quarters · filed 2025-02-13 | $1.52B derived: sum of 3 quarters · filed 2025-02-13 | $1.93B derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $523.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $1.05B derived: sum of 2 quarters · filed 2025-02-13 | $1.46B derived: sum of 3 quarters · filed 2025-02-13 | $1.82B 10-K · filed 2025-02-13 |
| 2022-09-30 | $522.35M 10-Q · filed 2023-11-02 | $938.85M derived: sum of 2 quarters · filed 2023-11-02 | $1.30B 10-Q · filed 2023-11-02 | $1.75B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $416.50M 10-Q · filed 2023-08-03 | $776.50M 10-Q · filed 2023-08-03 | $1.23B derived: sum of 3 quarters · filed 2024-02-15 | $1.60B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $359.99M 10-Q · filed 2023-05-04 | $813.09M derived: sum of 2 quarters · filed 2024-02-15 | $1.18B derived: sum of 3 quarters · filed 2024-02-15 | $1.55B derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $453.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $822.41M derived: sum of 2 quarters · filed 2024-02-15 | $1.19B derived: sum of 3 quarters · filed 2024-02-15 | $1.55B 10-K · filed 2024-02-15 |
| 2021-09-30 | $369.31M 10-Q · filed 2022-10-27 | $736.02M derived: sum of 2 quarters · filed 2022-10-27 | $1.10B 10-Q · filed 2022-10-27 | $1.46B derived: sum of 4 quarters · filed 2022-10-27 |
| 2021-06-30 | $366.71M 10-Q · filed 2022-07-28 | $730.53M 10-Q · filed 2022-07-28 | $1.09B derived: sum of 3 quarters · filed 2022-07-28 | $1.44B derived: sum of 4 quarters · filed 2022-07-28 |
| 2021-03-31 | $363.82M 10-Q · filed 2022-04-28 | $721.60M derived: sum of 2 quarters · filed 2022-04-28 | $1.07B derived: sum of 3 quarters · filed 2022-04-28 | $1.38B derived: sum of 4 quarters · filed 2022-04-28 |
| 2020-12-31 | $357.78M 10-K · filed 2021-02-11 | $708.84M derived: sum of 2 quarters · filed 2021-10-28 | $1.01B derived: sum of 3 quarters · filed 2021-10-28 | $1.32B 10-K · filed 2023-02-23 |
| 2020-09-30 | $351.05M 10-Q · filed 2021-10-28 | $653.87M derived: sum of 2 quarters · filed 2021-10-28 | $963.51M 10-Q · filed 2021-10-28 | $1.33B derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $302.82M 10-Q · filed 2021-08-03 | $612.46M 10-Q · filed 2021-08-03 | $982.21M derived: sum of 3 quarters · filed 2021-08-03 | $1.27B derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $309.63M 10-Q · filed 2021-04-29 | $679.39M derived: sum of 2 quarters · filed 2021-04-29 | $965.75M derived: sum of 3 quarters · filed 2021-04-29 | $1.25B derived: sum of 4 quarters · filed 2021-04-29 |
| 2019-12-31 | $369.75M 10-K · filed 2021-02-11 | $656.11M derived: sum of 2 quarters · filed 2021-02-11 | $937.10M derived: sum of 3 quarters · filed 2021-02-11 | $1.16B 10-K · filed 2022-02-10 |
| 2019-09-30 | $286.36M 10-K · filed 2021-02-11 | $567.35M derived: sum of 2 quarters · filed 2021-02-11 | $789.43M 10-Q · filed 2020-11-05 | $1.03B derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $280.99M 10-K · filed 2021-02-11 | $503.07M 10-Q · filed 2020-08-06 | $744.46M derived: sum of 3 quarters · filed 2021-02-11 | $1.00B derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $222.08M 10-K · filed 2021-02-11 | $463.47M derived: sum of 2 quarters · filed 2021-02-11 | $720.10M derived: sum of 3 quarters · filed 2021-02-11 | $942.36M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $241.39M 10-K · filed 2020-02-13 | $498.02M derived: sum of 2 quarters · filed 2020-02-13 | $720.28M derived: sum of 3 quarters · filed 2020-02-13 | $889.58M 10-K · filed 2021-02-11 |
| 2018-09-30 | $256.63M 10-K · filed 2020-02-13 | $478.89M derived: sum of 2 quarters · filed 2020-02-13 | $648.19M 10-Q · filed 2019-10-31 | $833.42M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $222.26M 10-K · filed 2020-02-13 | $391.56M 10-Q · filed 2019-08-06 | $576.79M derived: sum of 3 quarters · filed 2020-02-13 | $719.69M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $169.30M 10-K · filed 2020-02-13 | $354.53M derived: sum of 2 quarters · filed 2020-02-13 | $497.43M derived: sum of 3 quarters · filed 2020-02-13 | $633.83M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $185.23M 10-K · filed 2019-02-14 | $328.12M derived: sum of 2 quarters · filed 2019-02-14 | $464.53M derived: sum of 3 quarters · filed 2019-02-14 | $590.00M 10-K · filed 2020-02-13 |
| 2017-09-30 | $142.90M 10-K · filed 2019-02-14 | $279.30M derived: sum of 2 quarters · filed 2019-02-14 | $404.77M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $136.41M 10-K · filed 2019-02-14 | $261.88M derived: sum of 2 quarters · filed 2019-02-14 | ||
| 2017-03-31 | $125.47M 10-K · filed 2019-02-14 | |||
| 2016-12-31 | $471.75M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |